GlassScriptPhysician profile
Paula V Ross
NPI 1316904949
$3,524.76
in general payments reported to CMS, 2019-2025
27 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $64.07 · 2021: $317 · 2022: $667 · 2023: $575 · 2024: $805 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.02 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,017.31 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $543.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $242.28 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $230.46 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $224.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.22 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $173.54 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $159.42 | 2022 | |
| Pfizer INC. | $116.31 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $99.50 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $95.30 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $59.24 | 2024 | |
| Alnylam Pharmaceuticals INC. | $41.95 | 2023-2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.05 | 2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $33.62 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $31.05 | 2024 | Nexletol |
| Cvrx, INC. | $30.61 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $26.74 | 2019-2020 | |
| Amarin Pharma, INC. | $25.46 | 2019-2021 | |
| Edwards Lifesciences Corporation | $23.40 | 2024 | Sapien 3 Ultra Resilia |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Irhythm Technologies, INC. | $23.13 | 2024 | Zio Xt Patch, Zio Monitor |
| Cardiva Medical, INC. | $19.87 | 2022 | |
| Heartflow, INC. | $18.28 | 2023 | Ffrct |
| Abbott Laboratories | $17.06 | 2024 | Mitraclip |
| Boston Scientific Corporation | $14.30 | 2023 | Watchman Access System |
| Chiesi USA, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.